Table 2 Cilengitide exposure and response

From: Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part

 

Cohort 1 ( n =3)

Cohort 2 ( n =3)

Cohort 3 ( n =4)

Cilengitide dose

500 mg

1000 mg

2000 mg

Median duration of cilengitide administration (range), weeks

23.3 (14–25)

42.4 (35–57)

16.3 (12–45)

Best overall tumour response, n

 Complete response

0

0

0

 Partial response

0

1

3

 Stable disease

3

2

1

 Progressive disease

0

0

0

Back to article page